

## **Answers to reviewers**

Reviewer 1:

This is a brief but excellent review.

**Answer: Thank you**

Reviewer 2:

This Editorial evaluates ongoing and published trials on immune checkpoint inhibitors in hepatocellular carcinoma and biliary tract cancers, esophageal, gastric, pancreatic, colorectal and anal cancers and discusses future perspectives of these agents in gastrointestinal cancers. The data from both published and ongoing trials are systematically summarized and presented in Table 1, the future perspectives are given perfectly soundly, yet are maybe a little short and the References are pertinent. However, the language deserves some polishing (also some typos in the text) and I suggest that the authors explain all abbreviations in the text and in the Table meticulously.

**Answer: the language was polished and abbreviations were added .**

Reviewer 3:

Nice overview of a rapidly developing field.

**Answer: Thank you**